The Prognostic Value of Plasma Cell-Free DNA Concentration in the Prostate Cancer: A Systematic Review and Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 29

PMID 33777743

Citations 23

Authors

Hongtao Liu

Yuzhen Gao

Somayeh Vafaei

Xiao Gu

Xiaoli Zhong

Affiliations

Soon will be listed here.

Abstract

Objective: By virtue of largely disparate clinical outcomes of prostate cancer (PCA), there is a pressing need to search for useful biomarkers for PCA prognosis. Cell-free DNA (cfDNA) is a promising biomarker for detecting, monitoring, and predicting survival of prostate cancer (PCA). However, the utility of total cfDNA quantitation in PCA in clinical setting remains elusive. Here, we performed a thorough meta-analysis to assess the prognostic value of cfDNA concentration for patients with PCA. In addition, we tested the possibility of the combination of PSA and cfDNA test results to improve the prediction power in PCA prognosis.

Method And Materials: More than six databases, including PubMed, Web of Science, Medline, PMC, EMBASE and the Cochrane Library were searched. Results yielded all eligible articles from the date of inception to June 30, 2020. Continuous, diagnostic, and prognostic variables in cfDNA in PCA were included in the meta-analysis by STATA.

Results: A total of 23 articles were enrolled in our meta-analysis: 69.6% (16/23) were related to diagnosis, and 56.5% (13/23) were related to prognosis. The pooled concentration of cfDNA in PCA patients was significantly higher than in the control group (SMD = 0.89, 95%CI = 0.53, 1.26), mirroring results for the prostate-specific antigen (PSA). For the detection test variables, the SROC with 95%CI was 0.87 (0.84-0.90) for cfDNA concentration. In terms of prognostic variables, the concentrations of cfDNA were significantly related with progression-free survival (PFS, logHR = 0.84 (95%CI0.39, 1.28) and overall survival [OS, log HR = 0.60 (95%CI0.29, 0.90)]. Lastly, the test showed no significant publication bias in the present meta-analysis, excluding the diagnostic meta-analysis.

Conclusions: The concentration of cell-free DNA is high in the prostate cancer patients. The present study substantiates the prognostic value of the cfDNA concentration. High concentration cfDNA correlates with poor disease outcome of CRPC. The study cohort with large sample size is needed to evaluate the prognosis value of cfDNA in the future. We also emphasized that combination of PSA and cf DNA quantitation is important in future large individual meta study.

Citing Articles

Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.

Chrenkova E, Studentova H, Hola K, Kahounova Z, Hendrychova R, Soucek K Front Oncol. 2024; 14:1394292.

PMID: 39319053 PMC: 11420116. DOI: 10.3389/fonc.2024.1394292.

Liquid biopsy to personalize treatment for metastatic prostate cancer.

Lopez-Valcarcel M, Lopez-Campos F, Zafra J, Cienfuegos I, Ferri M, Barrado M Am J Transl Res. 2024; 16(5):1531-1549.

PMID: 38883349 PMC: 11170619. DOI: 10.62347/DICU9510.

Blood-Based DNA Methylation Analysis by Multiplexed OBBPA-ddPCR to Verify Indications for Prostate Biopsies in Suspected Prostate Cancer Patients.

Friedemann M, Jandeck C, Tautz L, Gutewort K, von Rein L, Sukocheva O Cancers (Basel). 2024; 16(7).

PMID: 38611002 PMC: 11010987. DOI: 10.3390/cancers16071324.

Association between thyroid disorders and extra-thyroidal cancers, a review.

Jia X, Li J, Jiang Z Clin Transl Oncol. 2024; 26(9):2075-2083.

PMID: 38491294 DOI: 10.1007/s12094-024-03434-3.

Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study.

Huang H, Chen C, Chang K, Lee M, Lee C, Chao Y J Transl Med. 2023; 21(1):714.

PMID: 37821919 PMC: 10566053. DOI: 10.1186/s12967-023-04424-9.

References

Fernandez-Garcia D, Hills A, Page K, Hastings R, Toghill B, Goddard K . Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res. 2019; 21(1):149. PMC: 6924016. DOI: 10.1186/s13058-019-1235-8. View

Tissot C, Toffart A, Villar S, Souquet P, Merle P, Moro-Sibilot D . Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015; 46(6):1773-80. DOI: 10.1183/13993003.00676-2015. View

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner E . Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discov. 2018; 8(4):444-457. DOI: 10.1158/2159-8290.CD-17-0937. View

Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G . Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004; 205(2):173-80. DOI: 10.1016/j.canlet.2003.11.023. View

Boddy J, Gal S, Malone P, Harris A, Wainscoat J . Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res. 2005; 11(4):1394-9. DOI: 10.1158/1078-0432.CCR-04-1237. View

Garnick M . Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993; 118(10):804-18. DOI: 10.7326/0003-4819-118-10-199305150-00008. View

Kienel A, Porres D, Heidenreich A, Pfister D . cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer. J Urol. 2015; 194(4):966-71. DOI: 10.1016/j.juro.2015.04.055. View

Mehra N, Penning M, Maas J, van Daal N, Giles R, Voest E . Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res. 2007; 13(2 Pt 1):421-6. DOI: 10.1158/1078-0432.CCR-06-1087. View

Vandekerkhove G, Chi K, Wyatt A . Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genet. 2017; 228-229:151-158. DOI: 10.1016/j.cancergen.2017.08.003. View

10.

Reis I, Ramachandran K, Speer C, Gordian E, Singal R . Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. Br J Cancer. 2015; 113(3):460-8. PMC: 4522641. DOI: 10.1038/bjc.2015.240. View

11.

Ellinger J, Muller S, Stadler T, Jung A, von Ruecker A, Bastian P . The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol. 2009; 29(2):124-9. DOI: 10.1016/j.urolonc.2009.05.010. View

12.

Wang J, Han X, Sun Y . DNA methylation signatures in circulating cell-free DNA as biomarkers for the early detection of cancer. Sci China Life Sci. 2017; 60(4):356-362. DOI: 10.1007/s11427-016-0253-7. View

13.

Prensner J, Rubin M, Wei J, Chinnaiyan A . Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012; 4(127):127rv3. PMC: 3799996. DOI: 10.1126/scitranslmed.3003180. View

14.

Papadopoulou E, Davilas E, Sotiriou V, Georgakopoulos E, Georgakopoulou S, Koliopanos A . Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann N Y Acad Sci. 2006; 1075:235-43. DOI: 10.1196/annals.1368.032. View

15.

Slavin T, Banks K, Chudova D, Oxnard G, Odegaard J, Nagy R . Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018; :JCO1800328. PMC: 6286162. DOI: 10.1200/JCO.18.00328. View

16.

Gordian E, Ramachandran K, Reis I, Manoharan M, Soloway M, Singal R . Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol Biomarkers Prev. 2010; 19(8):1984-91. DOI: 10.1158/1055-9965.EPI-10-0287. View

17.

Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S . Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. 2018; 74(3):283-291. PMC: 6090941. DOI: 10.1016/j.eururo.2018.02.013. View

18.

Fan G, Zhang K, Yang X, Ding J, Wang Z, Li J . Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review. PLoS One. 2017; 12(2):e0171991. PMC: 5302475. DOI: 10.1371/journal.pone.0171991. View

19.

Di Meo A, Bartlett J, Cheng Y, Pasic M, Yousef G . Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer. 2017; 16(1):80. PMC: 5391592. DOI: 10.1186/s12943-017-0644-5. View

20.

Panagopoulou M, Karaglani M, Balgkouranidou I, Biziota E, Koukaki T, Karamitrousis E . Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. Oncogene. 2019; 38(18):3387-3401. DOI: 10.1038/s41388-018-0660-y. View